IP Library Granted Patent US 8,058,292
Granted Patent B2
US 8,058,292 · App. 12/786,043 · Granted Nov 15, 2011

Therapeutic agents useful for treating pain

Assignee: Purdue Pharma L.P.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,292
App. No.
12/786,043
Granted
Nov 15, 2011
Kind
B2
Abstract

The invention provides a compound of formula (I): (where R 1 , Q, A and R 2 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Pyridine-alkynyl Compound”); pharmaceutical compositions comprising an effective amount of a Pyridine-alkynyl Compound; and methods for treating or preventing a condition such as pain, urinary incontinence, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, a seizure, stroke, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Pyridine-alkynyl Compound.

Claims (41)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is -halo, —CH 3 , —CF 3 , —NO 2 , —CN or —H;

Q is:

R 3 and R 4 are independently —CH 2 —, —CH(CH 3 )— or —C(O)—;

J is —N(H)— or —O—;

A is —C(O)— or —CH 2 —;

R 2 is —(C 1 -C 6 )alkyl, —(C 3 -C 8 )cycloalkyl, -phenyl, -naphthyl, or —(C 14 )aryl, each of which is unsubstituted or substituted with one or more R 5 groups;

R 5 is -halo, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkoxy or —OC(halo) 3 ;

a is 0 and b is 0;

each halo is independently —F, —Cl, —Br or —I; and

wherein the compound is optionally an optical isomer, a mixture of optical isomers, or a racemic mixture.

2. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

3. The compound of claim 1 , wherein A is —C(O)—.

4. The compound of claim 1 , wherein R 1 is -halo.

5. The compound of claim 3 , wherein R 1 is -halo.

6. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 5 and a pharmaceutically acceptable carrier or excipient.

7. The compound of claim 5 , wherein R 2 is -phenyl which is substituted with one or more R 5 groups.

8. The compound of claim 7 , wherein J is N(H), and R 3 and R 4 are each —CH 2 —.

9. The compound of claim 7 , wherein J is O, and R 3 and R 4 are each —CH 2 —.

10. The compound of claim 5 , wherein R 2 is -phenyl which is unsubstituted.

11. The compound of claim 10 , wherein J is N(H), and R 3 and R 4 are each —CH 2 —.

12. The compound of claim 10 , wherein J is O, and R 3 and R 4 are each —CH 2 —.

13. The compound of claim 1 , wherein R 1 is —NO 2 .

14. The compound of claim 3 , wherein R 1 is —NO 2 .

15. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 14 and a pharmaceutically acceptable carrier or excipient.

16. The compound of claim 14 , wherein R 2 is -phenyl which is substituted with one or more R 5 groups.

17. The compound of claim 16 , wherein J is N(H), and R 3 and R 4 are each —CH 2 —.

18. The compound of claim 16 , wherein J is O, and R 3 and R 4 are each —CH 2 —.

19. The compound of claim 14 , wherein R 2 is -phenyl which is unsubstituted.

20. The compound of claim 19 , wherein J is N(H), and R 3 and R 4 are each —CH 2 —.

21. The compound of claim 19 , wherein J is O, and R 3 and R 4 are each —CH 2 —.

22. The compound of claim 1 , wherein at least one of R 3 or R 4 is —C(O)—.

23. The compound of claim 1 , wherein A is —CH 2 —.

24. The compound of claim 23 , wherein R 1 is —NO 2 and R 2 is -phenyl which is unsubstituted or substituted with one or more R 5 groups.

25. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 24 and a pharmaceutically acceptable carrier or excipient.

26. The compound of claim 24 , wherein J is N(H), and R 3 and R 4 are each —CH 2 —.

27. The compound of claim 24 , wherein J is O, and R 3 and R 4 are each —CH 2 —.

28. A compound of formula:

or a pharmaceutically acceptable salt thereof.

29. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 28 and a pharmaceutically acceptable carrier or excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2010
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 024444/0876 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2010
From: KYLE, DONALD J.; SUN, QUN; ZHOU, XIAOMING
To: EURO-CELTIQUE S.A.
Reel/Frame 024431/0424 →
Continuity (4)
Division 11317832 · Dec 22, 2005
Continuation PCTUS2004021246 · Jul 1, 2004
Provisional Application 60484881 · Jul 3, 2003
Related Publication 20100256111A1 · Oct 7, 2010